ED&I logo
ED and I

Paving the Way for Diverse & Equitable Next Generation
Precision Medicine Clinical Trials

Establishing Collaborative Strategies to Improve Recruitment of Historically Marginalized Communities in Clinical Trials to Ensure Future Precision Medicines Are Fit For All

When: September 27, 8.00am – 5.00pm
Where: Boston - The Westin Boston Seaport District

Note: This meeting is taking place in-person only and online attendance will not be available

DOWNLOAD THE EVENT GUIDE
REGISTER YOUR INTEREST
VENUE & AGENDA DETAILS

Under-represented racial and ethnic populations have a long history of being mistreated by the health care system, researchers and the government. While the goal of precision medicine is to help everybody, the current research is largely based on the genes of people who are predominantly of white and European descent. As an industry, it is our responsibility to leverage our position to influence and drive action towards greater clinical trial diversity, equity and inclusion for all communities around the world.

That is why, the 4th Equity, Diversity & Inclusion in Precision Medicine Summit is returning to Boston to tackle the key barriers and challenges to clinical trial participation and discuss how to better align precision medicine trial participants with consumer populations.

You can expect case studies, presentations, panel discussions, roundtable discussions and networking opportunities to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities.

Do not miss out on this opportunity and join 80+ thought leaders in Boston to pave the way for the future of precision medicine clinical trials!

2022 Expert Speaker Faculty:

Anas El Turabi

Partner

McKinsey

Cristina Candida Quarta

Senior Medical Director

Alexion AstraZeneca Rare Diseases

Dana Dornsife

Founder, Chief Mission & Strategy Officer

Lazarex Cancer Foundation

Daniel Simon

Chief Business Officer

Revolution Medicines

Diana Merino Vega

Director, Oncology Translational Medicine Strategy & Portfolio

AstraZeneca

Elizabeth George

Senior Director, Diversity & Inclusion, Site & Patient Engagement

Labcorp Drug Development

Holly Smithson

Chief Executive Officer

Athena

Jasmine Sze

Director, Global Strategic Biomarkers Lead, Translational Medicine & Oncology Clinical Trial Diversity Lead

AstraZeneca

Leopold Sellner

Senior Medical Director

Takeda

Marcie Reeder

Director, Global Patient Affairs

BluePrint Medicines

Marjorie Petty, PhD, MSN

Senior Director, Clinical Operations & Medical Development

Spectrum Pharmaceuticals

Michaela Bowden

Senior Vice President, Biology & Translation

Flare Therapeutics

Qing Li, MD, PhD

Head of Clinical Biomarker & CDx Strategy

H3 Biomedicine

Samik Basu

Chief Scientific Officer

Cabaletta Bio

Saraswathy (Sara) Nochur

Chief Diversity, Equity & Inclusion Officer

Alnylam Pharmaceuticals

Siddha Kasar

Director, Oncology Precision Translational Medicine

Takeda

Tara Lehner

Vice President, Clinical Operations

Inmune Bio

Veronica Sandoval

Principal, Patient Inclusion & Health Equity, Chief Diversity Office

Genentech

Proud to Partner With:

Roche_Logo.svg
guardantlogo
thumbnail_Labcorp_Oncology_ CROPPED
DOWNLOAD THE EVENT GUIDE
REGISTER YOUR INTEREST
VENUE & AGENDA DETAILS

Note: This meeting is taking place in-person only and online attendance will not be available. Registration to the summit is free, but the event is operating with limited capacity.

What Will We Cover?

Please note: This meeting is taking place in-person only and online attendance will not be available.

This is the key in-person meeting for any precision medicine expert looking to draw from the experience of leading pharma and biotechs to help establish clear guidelines, expertise and processes to improve diversity in precision medicine clinical trials and therefore, enhance drug safety, improve drug development, and support fair access to medicines for all patients.

BulletPoint iea 2

Address financial, geographical and trust burdens to clinical trial participation and how precision medicine is aiming to mitigate them

BulletPoint iea 2

Tap into real-world examples that enabled more inclusivity in trial, as well as tailored strategies to engage with different communities

BulletPoint iea 2

Discuss best practices and opportunities to address diversity and inclusion in DCTs and maximize clinical enrollment

BulletPoint iea 2

Identify strategies to improve genomic representation and have a better understanding of the disease

BulletPoint iea 2

Explore how to overcome unconscious bias in clinical healthcare to build a fairer future for patients

What’s New in 2022?

From discussing practical steps to increase representation of historically marginalized communities in trials to highlighting how Decentralized Clinical Trials (DCTs) could help diversify the patient population, you can expect:

BulletPoint iea 2

Addressing Barriers to Increase Diversity in Precision Medicine Clinical Trials

BulletPoint iea 2

Translating Diversity in Leadership into Diversity in Clinical Enrollment

BulletPoint iea 2

Widening Your Global Patient Outreach with DCTs

BulletPoint iea 2

Building Inclusivity into Preclinical Precision Medicine Study Designs

BulletPoint iea 2

Discussing How to Overcome Unconscious Bias in Clinical Healthcare to Build a Fairer Future for Patients

DOWNLOAD THE EVENT GUIDE
REGISTER YOUR INTEREST
VENUE & AGENDA DETAILS

Note: This meeting is taking place in-person only and online attendance will not be available. Registration to the summit is free, but the event is operating with limited capacity.

VENUE & AGENDA

The World Clinical Biomarkers & CDx Summit and the Equity, Diversity & Inclusion in Precision Medicine Day will be held at:

The Westin Boston Seaport District
425 Summer St, Boston, MA, 02210

2
3
VIEW ACCOMMODATION OPTIONS

4th Equity, Diversity & Inclusion in Precision Medicine Day - Agenda

September 27, 8.00am – 5.00pm

8:00 am Registration Opens

8:50 am Hanson Wade Opening Remarks

8:55 am Chair’s Opening Remarks

Advancing Inclusive Research: Addressing Barriers to Increase Diversity in Precision Medicine Clinical Trials

9:00 am Presentation: Diversity in Clinical Trials: Where Are We Now & Where Do We Need to Be?

Synopsis

• What do we know about representativeness of clinical trial populations?
• Where are we making progress and where are we not?
• What do we know and don’t know about underlying drivers of underrepresentation in clinical trials?

9:30 am Panel Discussion: Overcoming Barriers & Limitations Affecting Precision Medicine Clinical Studies

  • Marcie Reeder Director, Global Patient Affairs, BluePrint Medicines
  • Michaela Bowden Senior Vice President, Biology & Translation, Flare Therapeutics
  • Marjorie Petty, PhD, MSN Senior Director, Clinical Operations & Medical Development, Spectrum Pharmaceuticals
  • Tara Lehner Vice President, Clinical Operations, INmune Bio
  • Elizabeth George Senior Director, Diversity & Inclusion, Site & Patient Engagement, Labcorp Drug Development

Synopsis

• Addressing financial, geographical and trust burdens to clinical trial participation and how precision medicine is aiming to mitigate them
• Practical steps to increase representation of historically marginalized communities in clinical trials
• Regardless of institutions’ efforts, what remains the same and needs a different type of approach?

10:00 am Presentation: A Story of Success: Characterizing the Next Generation of Clinical Trial Populations

  • Veronica Sandoval Principal, Patient Inclusion & Health Equity, Chief Diversity Office, Genentech

Synopsis

• Addressing successful strategies to engage with different communities
• Deciphering methods to understand representation of disease status and incidence rates
• Analyzing different ways and parameters to measure success in precision medicine clinical trial enrollment

10:30 am Networking Break

11:30 am Fireside Chat: How to Close the Gap Between the TALK & the WALK towards DE&I in Clinical Trials

Synopsis

• Proven methods for trial participation recruitment
• Pathways for empowering more patients to ask the important questions and understanding the benefit of clinical trial participation
• Strategies for physicians to educate patients and instill trust

12:00 pm Presentation: Under-Representation of Minorities with Certain Hematologic Malignancies in Cancer Clinical Trials

Synopsis

• Under-representation of minorities with certain hematologic malignancies in cancer clinical trials (multiple myeloma, lymphoma & leukaemia)
• Real-world example that enabled more inclusivity in trials
• Moving forward: tailored strategies to engage with different communities

12:30 pm Lunch Networking Break

Leveraging Oncology DCTs Effectively: Reinventing Enrollment Approaches

1:30 pm Panel Discussion: Widening Your Global Patient Outreach with DCTs

Synopsis

• Discussing best practices and opportunities to address diversity and inclusion in DCTs and maximize clinical enrollment
• Analyzing new ways to broaden eligibility criteria to accelerate drug development
• Assessing who would be more viable for telemedicine and how to attract them

2:00 pm Presentation: Pragmatic Insights to Enabling More Inclusive Clinical Studies

  • Jasmine Sze Director, Global Strategic Biomarkers Lead, Translational Medicine & Oncology Clinical Trial Diversity Lead, AstraZeneca

Synopsis

• Discuss necessary infrastructures when designing clinical trials to ensure successful enrollment of under-represented groups
• Opportunities & Actionable roadmap to enable more inclusivity in trials

2:30 pm Afternoon Networking Break

3:30 pm Presentation: Achieving Equity in Precision Medicine

  • Dana Dornsife Founder, Chief Mission & Strategy Officer, Lazarex Cancer Foundation

Synopsis

• Engaging communities in a culturally appropriate way – meeting people where they are
• Removing the financial barriers to participation
• How is the treatment pathway really determined?

4:00 pm Interactive Roundtable Discussions

Discussion A: Accountability Starts with Leadership: Translating Diversity in Leadership into Diversity in Clinical Enrollment

  • Michaela Bowden Senior Vice President, Biology & Translation, Flare Therapeutics

Synopsis

• Assessing the value of including diverse leaders in trial teams
• Identifying who are the influencers within the patients’ circles and how to interact with them
• Discussing how cross-functional collaboration between organizations can help achieve health equity

Discussion B: Bridging the Preclinical-Clinical Boundary: Building Inclusivity into Preclinical Precision Medicine Study Designs

  • Samik Basu Chief Scientific Officer, Cabaletta Bio

Synopsis

• Strategies to improve genomic representation and better understanding of the disease
• Identifying gaps in precision medicine research and development
• Understanding and identifying the source of patient distrust on precision medicine preclinical and
clinical trials

Discussion C: How to Overcome Unconscious Bias in Clinical Healthcare to Build a Fairer Future for Patients

  • Jasmine Sze Director, Global Strategic Biomarkers Lead, Translational Medicine & Oncology Clinical Trial Diversity Lead, AstraZeneca

Synopsis

• Identifying the potential impact of bias on precision medicine clinical practice and how to mitigate them
• Recognizing judgments made during trial recruitment processes
• How to tailor your precision medicine study design based on the racial disparities of the disease you are studying

5:00 pm Closing Remarks & End of ED&I in Precision Medicine Summit

Proud to Partner With:

Roche_Logo.svg
guardantlogo
thumbnail_Labcorp_Oncology_ CROPPED
DOWNLOAD THE EVENT GUIDE
REGISTER YOUR INTEREST
BECOME A PARTNER

Note: This meeting is taking place in-person only and online attendance will not be available. Registration to the summit is free, but the event is operating with limited capacity.